Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-05-27

Pre-clinical improvement of combined immunotherapy and chemotherapy for a new variant Creutzfeldt-Jakob disease

Cel

Tees are invariably fatal and are still incurable. Recent reports have shown that anti-Prepuce antibodies reduce Prep’s in infected-infected cells. Based on this data, we have infused anti-Prep antibody Fib fragments intracerebroventricularly in FVB mice with experimental scrape and demonstrated a delay in the clinical signs. The aims of this project are:
(i) to confirm these encouraging results in mice with experimental scrape or BSE,
(ii) to optimise immunotherapy protocols (intracerebroventricular and intraperitoneal),
(iii) to combine this immunotherapy with emerging chemotherapeutic agents including the chlorpromazine/aquamarine regimen, and
(iv) to rationally improve the anti-Prep antibodies, by creating chimerical constructs with targeted transcytosis through the blood/brain endothelium. These studies will culminate in phase I clinical trials in human niche and CJD patients.

Zaproszenie do składania wniosków

Data not available

System finansowania

CSC - Cost-sharing contracts

Koordynator

THE NETHERLANDS CANCER INSTITUTE / ANTONI VAN LEEUWENHOEK HOSPITAL
Wkład UE
Brak danych
Adres
121,Plesmanlaan 121
1066 CX AMSTERDAM
Niderlandy

Zobacz na mapie

Koszt całkowity
Brak danych

Uczestnicy (3)